Apr 22, 26SELLBooth Bruce· 5,900 sh @ $89.96−$531K↗
Apr 22, 26SELLChadwick Jeremy G· Chief Operating Officer300 sh @ $90.00−$27K↗
Apr 22, 26SELLBooth Bruce· 88 sh @ $90.08−$8K↗
Apr 22, 26SELLBooth Bruce· 12 sh @ $90.08−$1K↗
Apr 15, 26SELLBooth Bruce· 2,750 sh @ $90.10−$248K↗
Apr 15, 26SELLBooth Bruce· 2,200 sh @ $89.95−$198K↗
Apr 15, 26SELLChadwick Jeremy G· Chief Operating Officer1,300 sh @ $90.00−$117K↗
Apr 15, 26SELLBooth Bruce· 385 sh @ $90.10−$35K↗
Apr 14, 26SELLChadwick Jeremy G· Chief Operating Officer5,251 sh @ $90.00−$473K↗
Apr 14, 26SELLBooth Bruce· 4,159 sh @ $89.97−$374K↗
Apr 14, 26SELLGoodman Noah· Chief Business Officer1,347 sh @ $90.00−$121K↗
Apr 10, 26SELLGoodman Noah· Chief Business Officer2,000 sh @ $87.35−$175K↗
Apr 9, 26SELLGoodman Noah· Chief Business Officer3,094 sh @ $86.62−$268K↗
Apr 9, 26SELLGoodman Noah· Chief Business Officer2,670 sh @ $87.11−$233K↗
Apr 9, 26SELLGoodman Noah· Chief Business Officer2,500 sh @ $89.00−$223K↗
Apr 1, 26SELLChadwick Jeremy G· Chief Operating Officer13,540 sh @ $85.41−$1.16M↗
Apr 1, 26SELLRidloff Elena· director3,400 sh @ $85.19−$290K↗
Apr 1, 26SELLRidloff Elena· director1,200 sh @ $86.05−$103K↗
Apr 1, 26SELLChadwick Jeremy G· Chief Operating Officer1,100 sh @ $86.05−$95K↗
Mar 31, 26SELLChadwick Jeremy G· Chief Operating Officer7,600 sh @ $85.38−$649K↗

🐶 Hiring Signal

next earnings Nov 3, 2026

26 open roles at Kymera Therapeutics, Inc. →

Where Kymera Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaImmunology & Inflammation 24 Dermatology 1 Respiratory 1

departmentClinical 3 R&D / Discovery 3 Medical Affairs 3 Market Access 2 People & Talent 1 Quality 1

News

Chutes & Ladders—Legend CEO departs without successor in place
Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…
fiercebiotech · 15d ago

Data sources

SEC EDGAR

last refreshed just now

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

PUBLIC COMPANY

save

$KYMRKymera Therapeutics, Inc.

$KYMR117.39+2.60%

Watertown, MA, USupdated 3h ago

Website SEC EDGAR Yahoo Finance

community read0 votes

pipeline

marketed

phase 3

catalysts ytd

approvals ytd

recalls ytd

Pipeline(1)

pipeline depth1 products

1Phase 2

Phase 2

KT-621

Eosinophilic Asthma

Upcoming

Kymera Therapeutics, Inc. earnings

Kymera Therapeutics, Inc.

→

Recent(90d)

nothing in the last 90 days

view all catalysts →

Active trials

phase2A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitisrecruitingn=200
phase2A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthmarecruitingn=264
phase1First-in-human Study of Orally Administered KT-579 in Healthy Adult Participantsrecruitingn=96
phase1Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)completedn=22
phase1First-in-human Study of Orally Administered KT-621 in Healthy Adult Participantscompletedn=118
phase1Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumorscompletedn=56
phase1Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumorscompletedn=52
phase1Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHLcompletedn=7

more trials →

Insider activity

source: SEC Form 4

open-market buys + sells

Apr 22, 26SELLBooth Bruce· 5,900 sh @ $89.96−$531K↗
Apr 22, 26SELLChadwick Jeremy G· Chief Operating Officer300 sh @ $90.00−$27K↗
Apr 22, 26SELLBooth Bruce· 88 sh @ $90.08−$8K↗
Apr 22, 26SELLBooth Bruce· 12 sh @ $90.08−$1K↗
Apr 15, 26SELLBooth Bruce· 2,750 sh @ $90.10−$248K↗
Apr 15, 26SELLBooth Bruce· 2,200 sh @ $89.95−$198K↗
Apr 15, 26SELLChadwick Jeremy G· Chief Operating Officer1,300 sh @ $90.00−$117K↗
Apr 15, 26SELLBooth Bruce· 385 sh @ $90.10−$35K↗
Apr 14, 26SELLChadwick Jeremy G· Chief Operating Officer5,251 sh @ $90.00−$473K↗
Apr 14, 26SELLBooth Bruce· 4,159 sh @ $89.97−$374K↗
Apr 14, 26SELLGoodman Noah· Chief Business Officer1,347 sh @ $90.00−$121K↗
Apr 10, 26SELLGoodman Noah· Chief Business Officer2,000 sh @ $87.35−$175K↗
Apr 9, 26SELLGoodman Noah· Chief Business Officer3,094 sh @ $86.62−$268K↗
Apr 9, 26SELLGoodman Noah· Chief Business Officer2,670 sh @ $87.11−$233K↗
Apr 9, 26SELLGoodman Noah· Chief Business Officer2,500 sh @ $89.00−$223K↗
Apr 1, 26SELLChadwick Jeremy G· Chief Operating Officer13,540 sh @ $85.41−$1.16M↗
Apr 1, 26SELLRidloff Elena· director3,400 sh @ $85.19−$290K↗
Apr 1, 26SELLRidloff Elena· director1,200 sh @ $86.05−$103K↗
Apr 1, 26SELLChadwick Jeremy G· Chief Operating Officer1,100 sh @ $86.05−$95K↗
Mar 31, 26SELLChadwick Jeremy G· Chief Operating Officer7,600 sh @ $85.38−$649K↗

🐶 Hiring Signal

next earnings Nov 3, 2026

26 open roles at Kymera Therapeutics, Inc. →

Where Kymera Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaImmunology & Inflammation 24 Dermatology 1 Respiratory 1

departmentClinical 3 R&D / Discovery 3 Medical Affairs 3 Market Access 2 People & Talent 1 Quality 1

News

Chutes & Ladders—Legend CEO departs without successor in place
Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…
fiercebiotech · 15d ago

Data sources

SEC EDGAR

last refreshed just now

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

$KYMRKymera Therapeutics, Inc.

Pipeline(1)

Upcoming

Recent(90d)

Active trials

Insider activity

open-market buys + sells

News

Report a data issue

comments(0)

$KYMRKymera Therapeutics, Inc.

Pipeline(1)

Upcoming

Recent(90d)

Active trials

Insider activity

open-market buys + sells

News

Report a data issue

comments(0)

$KYMRKymera Therapeutics, Inc.

Pipeline(1)

📅 Upcoming

🕒 Recent(90d)

Active trials

Insider activity

open-market buys + sells

News

comments(0)

$KYMRKymera Therapeutics, Inc.

Pipeline(1)

📅 Upcoming

🕒 Recent(90d)

Active trials

Insider activity

open-market buys + sells

News

comments(0)

Upcoming

Recent(90d)

Upcoming

Recent(90d)